Epic Elite Mitral; Epic Elite Aortic; Epic Supra G3 valves
ABBOTT MEDICAL · Decision date Jun 22, 2026
What did the FDA approve?
FDA records P040021/S061 as a supplement to PMA P040021, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Jun 22, 2026.
FDA approval order statement
Approval for a next generation of the Epic family of tissue heart valves, collectively referred to as Epic Elite/G3. The changes to the Epic Elite/G3 valves include the addition of an expansion feature on the stent to facilitate future Valve-in-Valve (ViV) procedures, a change in stent material to an equivalent material from the same supplier, and minor marking and suture changes.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Cardiovascular
- Decision date
- Jun 22, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P040021/S061
- Regulatory pathway
- PMA supplement
- Applicant
- ABBOTT MEDICAL
- Product code
- LWR
- Decision code
- APPR
- Decision date
- Jun 22, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: heart-valve, non-allograft tissue.
- Applicant
- Abbott Medical
- Product code
- LWR
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P040021. Subsequent supplements may change the device or its indications.
FDA decision timeline
P040021 · Original PMA
SJM BIOCOR VALVE / SJM BIOCOR SUPRA VALVE
P040021/S059 · Related supplement
Epic Plus Stented Tissue Valve; Epic Max Stented Tissue Valve
P040021/S060 · Related supplement
Epic, Epic Supra, Epic Plus, Epic Plus Supra and Epic Max Stented Tissue Valve
P040021/S061 received
Application receipt date recorded by FDA.
P040021/S061 · FDA decision
Normal 180 Day Track
P040021/S062 · Related supplement
Epic, Epic Supra, Epic Plus, Epic Plus Supra and Epic Max, Epic Elite, and Epic Supra G3 Stented Tissue Valves
P040021/S063 · Related supplement
Epic Plus, Epic Plus Supra, Epic Max, Epic Elite, Epic Supra G3 Tissue Heart Valves
Timeline entries are records held by MedtechLedger for P040021. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P040021
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA approval | Aug 5, 2005 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Jul 29, 2025 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2025 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Aug 11, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Sep 18, 2026 | FDA |
Explore the linked device profile
Other records with product code LWR
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
EDWARDS INTUITY Elite Valve System (8300AB)P150036/S081 | Edwards Lifesciences, LLC | PMA supplement | Oct 28, 2026 | FDA |
| Edwards Lifesciences, LLC | PMA supplement | Oct 28, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 22, 2026 | FDA | |
EDWARDS INTUITY Elite Valve, Model 8300ABP150036/S080 | Edwards Lifesciences, LLC | PMA supplement | Jul 29, 2026 | FDA |
| Edwards Lifesciences, LLC | PMA supplement | Jul 29, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 177 County Rd. B E., St. Paul, MN, 55117
Sources and methodology
- Original FDA record: P040021/S061
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records